Celsion Corporation (CLSN)

[Rawnoc]

Nov 28 2011: 613 patients reviewed, 219 progression-free survival events
http://investor.celsion.com/releasedetail.cfm?ReleaseID=627024

Nov 9 2012: 701 patients, 380 progression-free survival events
http://investor.celsion.com/releasedetail.cfm?ReleaseID=720097

July 11 2011: 345 patients with no events
Nov 28 2011: 394 patients with no events
Nov 9 2012: 161 more patients had events

40.8% in the 12.5 month period with hundreds of the patients being in the trial for over 2 years.

60% recurrence rate for RFA+alone + 20% rate for RFA+ThermoDox = 40% average?

In other words Thermodox 200% vs. 33% necessary?

Probably doing something wrong. Hence 80% to 100% which is still a huge home run.